Search Results - "Shahavi, Vinayaka"

Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study by Gupta, Pawan Kumar, Maheshwari, Sunil, Cherian, Joe Joseph, Goni, Vijay, Sharma, Arun Kumar, Tripathy, Sujith Kumar, Talari, Keerthi, Pandey, Vivek, Sancheti, Parag Kantilal, Singh, Saurabh, Bandyopadhyay, Syamasis, Shetty, Naresh, Kamath, Surendra Umesh, Prahaldbhai, Purohit Sharad, Abraham, Jijy, Kannan, Suresh, Bhat, Samatha, Parshuram, Shivashankar, Shahavi, Vinayaka, Sharma, Akhilesh, Verma, Nikhil N., Kumar, Uday

“…Background: Osteoarthritis is a chronic, progressive, and degenerative condition with limited therapy options. Recently, biologic therapies have been an…”
Get full text

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia by Chandrakala, S., Toshniwal, Manoj, Halvawala, Mitesh, Padwal, Namita, Sidharthan, Neeraj, Malhotra, Pankaj, Prashantha, B., Ballikar, Riya, Shah, Sandip, Apte, Shashikant, Viswanathan, T. Kasi, Ramanan, Vijay, Sharma, Akhilesh, Pawar, Dattatray, Pawar, Roshan, Shahavi, Vinayaka

“…Romiplostim is a Food and Drug Administration (FDA)-approved therapy for immune thrombocytopenia (ITP). Biosimilar is a biological product that has no clinical…”
Get full text

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia by Chandrakala, S., Toshniwal, Manoj, Halvawala, Mitesh, Padwal, Namita, Sidharthan, Neeraj, Malhotra, Pankaj, Prashantha, B., Ballikar, Riya, Shah, Sandip, Apte, Shashikant, Viswanathan, T. Kasi, Ramanan, Vijay, Sharma, Akhilesh, Pawar, Dattatray, Pawar, Roshan, Shahavi, Vinayaka

“…[This corrects the article DOI: 10.1007/s12288-022-01602-5.]…”
Get full text

Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial by Aashish, Mondal, Arindam, Naskar, Siddiqi, Sheelu Shafiq, Bhosle, Deepak, Mallikarjuna, V J, Amol, Dange, Sanket, Sorate, Omkar, Gavali, Parth, Patel, Dhruvi, Hasnani, Durga, Prasad, Pradeep, Dalwadi, Suresh, Kumar, Vaishali, Pathak, Mayura, Chaudhari, Indraneel, Basu, Jayashri, Shembalkar, Arif, Fariooqui, Raghavendra, S K, Deepak, Varade, Ravindra, Thakkar, Shaishav, Bhanushali, Vijay, Gaikwad, Khan, Kamran, Mahajani, V V, Sharma, A D, Mayabhate, Mayur, Pawar, R R, Aiwale, A S, Vinayaka, Shahavi

“…Due to the progressive decline in β-cell function, it is often necessary to utilize multiple agents with complementary mechanisms of action to address various…”
Get full text

Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB®) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study by Rana, Parth, Deshmukh, Himanshu, Shah, Urmil, Kumar, Vinod, Kanungo, Sanghamitra, Singhal, Deepika, Mahapatra, Santosh Kumar, Vakharia, Ira, Jaiswal, Mukesh, Gondane, Ajitkumar, Vaidya, Pooja, Shahavi, Vinayaka, Shandilya, Harish, Pawar, Dattatray, Sharma, Akhilesh

“…This study aimed to compare efficacy, safety, and immunogenicity of the biosimilar ranibizumab in comparison with the Innovator Ranibizumab in treatment-naive…”
Get full text

A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin by Jain, Aditi, Vispute, Abhay, Dange, Amol, Naskar, Arindam, Mondal, Asish, Vivekanand, B., Sharma, Balram, Varade, Deepak, Shukla, Dhaiwat, Bhatia, Girish, Chaudhari, Harshal, Ram Babu, K., Gavali, Onkar, Sorate, Sanket, Bhanushali, Shaishav, Kothari, Vaibhav, Khandelwal, Vipul, Sharma, Akhilesh, Pawar, Roshan, Mayabhate, Mayur, Shahavi, Vinayaka, Rajput, Aashishsingh, Jaiswal, Mukesh

“…Introduction The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of dapagliflozin (10 mg) and linagliptin (5 mg) in…”
Get full text

Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study by Ajmani, Ajay Kumar, Agrawal, Aparna, Prasad, B.L.N., Basu, Indraneel, Shembalkar, Jayashree, Manikanth, Neeraj, Subrahmanyam, K.A.V., Srinivasa, M., Chawla, Manoj, Srivastava, Manoj Kumar, Jebasingh, Felix, Achappa, Basavaprabhu, Agrawal, R.P., Pulichikkat, Rakesh K., Meena, Ramdhan, Bhatia, Shailaja, Gupta, Sandeep Kumar, Dange, Amol, Srivastava, Ambrish, Trailokya, Abhijit, Shahavi, Vinayaka, Shende, Sachin

“…This study aimed to assess efficacy and safety of evogliptin versus sitagliptin, when added to background metformin therapy in Indian patients with…”
Get full text

A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase III Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection by Dube, Abhay, Deb, Ashish Kumar, Das, Chandan, Padhye, Devdatta, Bhalla, Hira, Basu, Indraneel, Bs, Madhu, Srivastava, Pankaj, Agarwal, Rajeev, Agrawal, Rajendra Prasad, Singh, Ram Murti, Kurlekar, Uttkrant, Pawar, Roshan, Shahavi, Vinayaka, Srivastava, Ambrish

“…Increasing resistance to currently available antimicrobials has led to the development of new agents. Arbekacin is aminoglycoside antibiotic currently used in…”
Get full text

Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial by Prabhash, Kumar, Deshmukh, Chetan, Malhotra, Hemant, Sharma, Atul, Jain, Minish, Dhamne, Nilesh, Nagarakar, Rajnish, Ganesan, Prasantha, Mahobia, Vijay K., Das, Chandan K., Kumar, Rejnish, Shivanna, Prakash S., Avaronnan, Manu P., Chaithanya, Puligundla K., Chaudhary, Vaibhav, Singh, Kartar, Aagre, Suhas, Ravishankar, Bellala, Mehta, Dhruv, Shilpa, Kandipalli, Maniar, Vashishth, Chatterjee, Koushik, Majumdar, Saroj D., Dana, Rohitashwa, Noronha, Vanita, Menon, Nandini, Sharma, Akhilesh, Pawar, Roshan, Shahavi, Vinayaka, Yadav, Rajiv, Aiwale, Amol

“…Biosimilar vs Innovator Cetuximab in Indian Head & Neck Cancer Patients…”
Get full text